What's Happening?
Indivior PLC has published results from a clinical trial indicating that rapid induction with SUBLOCADE® improves retention rates in opioid use disorder treatment. The study compared rapid induction, involving
a single dose of oral buprenorphine followed by a same-day SUBLOCADE injection, to standard induction, which requires at least seven days of oral buprenorphine adjustments. The rapid induction method showed higher retention rates, particularly among fentanyl-positive participants. The trial suggests that this approach could enhance patient engagement during the critical early weeks of treatment.
Why It's Important?
The findings from Indivior's study represent a significant advancement in the treatment of opioid use disorder, particularly in the context of the fentanyl crisis in the U.S. Rapid induction with SUBLOCADE could improve patient retention and outcomes, addressing a major challenge in addiction treatment. This approach may influence treatment protocols and policies, potentially leading to broader adoption of rapid induction methods. The study highlights the importance of innovative strategies in combating the opioid epidemic, which continues to impact communities across the U.S.
